Neural Stem Cell Therapy for Neurodegenerative Diseases

Neural Stem Cell Therapy for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Neural Stem Cell Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT03724136</td>
<td>I/II</td>
</tr>
<tr>
<td class="label">NCT04802733</td>
<td>I</td>
</tr>
<tr>
<td class="label">NCT03714355</td>
<td>I</td>
</tr>
<tr>
<td class="label">NCT03296656</td>
<td>I</td>
</tr>
</table>

Neural Stem Cell Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Neural Stem Cell Therapy for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Neural Stem Cell Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT03724136</td>
<td>I/II</td>
</tr>
<tr>
<td class="label">NCT04802733</td>
<td>I</td>
</tr>
<tr>
<td class="label">NCT03714355</td>
<td>I</td>
</tr>
<tr>
<td class="label">NCT03296656</td>
<td>I</td>
</tr>
</table>

Neural Stem Cell Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Neural stem cell (NSC) therapy represents a promising regenerative approach for neurodegenerative diseases. NSCs are multipotent progenitor cells capable of differentiating into [neurons](/entities/neurons), [astrocytes](/entities/astrocytes), and oligodendrocytes. They offer potential for replacing lost neurons, supporting surviving cells, and modulating the disease microenvironment. [@takahashi2020]

Mechanism of Action

Cell Replacement

• Differentiation into region-specific neurons
• Integration into existing neural circuits
• Restoration of neurotransmitter balance

Neurotrophic Support

• Secretion of BDNF, GDNF, NGF
• Support for endogenous neurogenesis
• Promotion of synaptic plasticity

Immunomodulation

• Reduction of neuroinflammation
• Modulation of microglial activation
• Creation of pro-regenerative microenvironment

Paracrine Signaling

• Exosome-mediated effects
• Secretion of anti-apoptotic factors
• Enhancement of angiogenesis

Clinical Applications

Parkinson's Disease

• Replacement of dopaminergic neurons
• Potential restoration of motor function
• Several clinical trials completed or ongoing
• fetal-derived and iPSC-derived approaches

Huntington's Disease

• Striatal neuron replacement
• May slow disease progression
• Early-phase clinical trials

Amyotrophic Lateral Sclerosis

• Motor neuron replacement
• Support of surviving motor neurons
• Immunomodulatory effects

Alzheimer's Disease

• Cholinergic neuron replacement
• Support of hippocampal function
• Currently in preclinical/early clinical stages

Stroke and TBI

• Most advanced clinical applications
• Functional recovery improvements
• Several Phase I/II trials completed

Types of Neural Stem Cells

Fetal-Derived NSCs

• Human fetal brain tissue-derived
• Well-characterized
• Ethical considerations

Adult-Derived NSCs

• From adult subventricular zone
• Autologous possible
• Limited expansion capacity

Induced Neural Stem Cells (iNSCs)

• Reprogrammed from somatic cells
• Autologous, patient-specific
• No ethical concerns

Embryonic Stem Cell-Derived

• Unlimited differentiation potential
• Allogeneic options
• Tumor risk concerns

Clinical Trials Overview

Dosage and Administration

Delivery Routes

• Intracerebral injection (most common)
• Intrathecal delivery
• Intravenous infusion
• Intranasal administration

Treatment Protocols

• Single or repeated doses
• Immunosuppression often required
• Long-term follow-up essential

Safety Considerations

Risks

• Tumor formation (teratoma)
• Immune rejection
• Intracranial hemorrhage
• Seizures
• Neurological deficits

Mitigation

• Careful cell characterization
• HLA matching
• Controlled differentiation
• Comprehensive monitoring

Research Directions

• Optimization of cell delivery
• Gene-edited NSCs for enhanced survival
• Combination with rehabilitation
• Biomarker development for patient selection
• Scalable manufacturing

See Also

• [Cell Replacement Therapy](/therapeutics/cell-replacement-therapy)
• [Stem Cell Therapy](/therapeutics/stem-cell-therapy)
• [Parkinson's Disease Treatment](/therapeutics/parkinsons-symptomatic-treatments)
• [GDNF Therapy](/therapeutics/gdnf-therapy-parkinsons)

Background

The study of Neural Stem Cell Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [NIH - Stem Cell Information](https://stemcells.nih.gov/)
• [ClinicalTrials.gov - Neural Stem Cell](https://clinicaltrials.gov/search?cond=neurodegenerative+stem+cell)
• [ISSCR - Stem Cell Research](https://www.isscr.org/)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
• [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12

Related Analyses:

• [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) &#x1f504;